Calendario›CORT›MOMENTUM
MOMENTUM
Study of the Prevalence of Endogenous Hypercortisolism in Patients With Resistant Hypertension (MOMENTUM)
Ensayo de CORCEPT THERAPEUTICS INC en Resistant Hypertension · Hypercortisolism (del registro, en inglés).
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 1.143
- Centros
- 50
- Fin del objetivo primario
- dic 2025
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en mar 2025.
Qué mide
To assess the prevalence of endogenous hypercortisolism in a population with resistant hypertension. (From enrollment to the end of the study which is approximately 4 weeks.) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThis is a non-interventional study to assess the prevalence of endogenous hypercortisolism (eHC) in patients with resistant hypertension (rHTN) and will enroll approximately 1000 patients at approximately 45 sites in the United States (US). Each patient will have an initial visit for screening. After eligibility is confirmed, a limited exam will be performed and demographic and medical history will be collected. Non-fasting labs and a urine collection will also be done. A second visit will be a fasting blood draw at 8 AM after taking 1 mg of dexamethasone the night before at 11 PM. Cortisol level and study labs will also be collected. After the lab results are obtained, a third visit will be scheduled only for patients with eHC and will include a non-fasting blood draw at 8 AM and scheduling of a non-contrast CT scan.
Más ensayos de CORT
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Relacorilant 150 mg | Fase 3 | En marcha, sin reclutar | mar 2025 (real) |
| Relacorilant 150 mg once daily | Fase 2 | Reclutando pacientes | ago 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Nenocorilant 200 mg | Fase 1/2 | Reclutando pacientes | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Dazucorilant 300 mg · DAZALS | Fase 2 | En marcha, sin reclutar | oct 2026 (prevista) |
| Miricorilant | Fase 1 | Reclutando pacientes | oct 2026 (prevista) |
| relacorilant | Fase 2 | En marcha, sin reclutar | dic 2026 (prevista) |
Todos los de CORT, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT06829537), actualizada en feb 2026.